The Trump administration’s crackdown on fraud, waste and abuse continues, with the Department of Justice last week launching a new effort targeting healthcare fraud. Experts think the new strike force ...

A rare type of cancer affecting the bile ducts of the liver now has its first FDA-approved targeted treatment, an intravenously infused medicine from Partner Therapeutics. The Friday regulatory ...

Capstan’s initial focus is the development of in vivo chimeric antigen receptor, or CAR T, therapies. CAR T-drugs are currently made from a patient’s own T cells, which are engineered in a lab before ...

AbbVie is joining the chase for new obesity drugs, but rather than getting a me-too GLP-1 drug, the pharmaceutical giant is landing rights to a clinical-stage molecule that goes after two novel ...

Although the goals of value-based care (VBC) are better outcomes and sustainable reimbursement, it won’t work if organizations can’t accurately attribute patients, providers, and encounters across an ...

Disagreements between providers and payers have been moving into the courtroom over the past few weeks. The California ...

It’s 2 a.m. A mother calls into a nurse triage line. Her baby isn’t screaming. She’s not rattling off symptoms. She just keeps saying, “something’s wrong.” And the nurse on the other end of that phone ...

Angelini Pharma is acquiring Catalyst Pharmaceuticals in a $4.1 billion deal that gives the Italy-based brain medicines company three commercialized rare disease products and entry into the U.S.

Roughly 31,000 Kaiser Permanente healthcare workers have walked off the job this week in California and Hawaii, protesting stalled contract negotiations and what they describe as unsafe staffing ...

Invitae’s business operations are heading to a new home. Under a bankruptcy auction, Labcorp was selected as the winning bidder for the firm’s genetic testing services, digital health solutions, and ...

The healthcare industry has faced a flurry of sweeping changes at the federal level since President Donald Trump took office. In recent months, healthcare leaders have scrambled to come up with ...

AstraZeneca is expanding its prospects in cardiometabolic disease, paying $1.2 billion to begin a partnership on eight programs that include obesity drug candidates with potential advantages over ...